Immunosuppression-reverting oligonucleotides inhibiting the expression of CD39

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11959083
APP PUB NO 20200224202A1
SERIAL NO

16340259

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention refers to immunosuppression-reverting oligonucleotides comprising 12 to 18 nucleotides, wherein at least one of the nucleotides is modified, and the oligonucleotide hybridizes with a nucleic acid sequence of an ectonucleotidase (NTPdase; CD73) of SEQ ID NO.1 (human), wherein the oligonucleotide inhibits at least 50% of the CD39 expression. The invention is further directed to a pharmaceutical composition comprising such oligonucleotide.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
SECARNA PHARMACEUTICALS GMBH & CO KGRUDOLF-BULTMANN-STR 4H 35039 MARBURG 35039

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Jaschinski, Frank Puchheim, DE 27 179
Thelemann, Tamara Munich, DE 3 0

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Oct 16, 2027
7.5 Year Payment $3600.00 $1800.00 $900.00 Oct 16, 2031
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 16, 2035
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00